Subject(s)
Breast Neoplasms/pathology , Histiocytoma, Benign Fibrous/diagnostic imaging , Skin Neoplasms/diagnosis , Skin Neoplasms/secondary , Aged , Dermoscopy , Diagnosis, Differential , Female , Histiocytoma, Benign Fibrous/chemistry , Humans , Immunohistochemistry , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Skin Neoplasms/chemistry , Skin Neoplasms/pathologyABSTRACT
No disponible
Subject(s)
Humans , Folliculitis/microbiology , Disease Outbreaks , Pseudomonas aeruginosa/pathogenicity , Pseudomonas Infections/transmission , Baths/adverse effects , Hydrotherapy/adverse effectsSubject(s)
Community-Acquired Infections/transmission , Disease Outbreaks , Folliculitis/microbiology , Hydrotherapy , Pseudomonas Infections/transmission , Pseudomonas aeruginosa/isolation & purification , Water Microbiology , Adult , Child , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Folliculitis/epidemiology , Humans , Lymphadenitis/microbiology , Male , Middle Aged , Pseudomonas Infections/epidemiology , Pseudomonas Infections/microbiology , Spain/epidemiologyABSTRACT
INTRODUCTION: Pharmacoeconomic studies examining the cost-effectiveness of biological agents to treat moderate-to-severe psoriasis in real-life clinical practice are scarce. The aim of this study was to assess the efficiency, in terms of incremental cost-effectiveness, of etanercept and adalimumab in a real clinical setting. METHODS: Direct and indirect costs were assessed from a Spanish societal perspective in a historical hospital cohort of patients with moderate-to-severe psoriasis attending a tertiary referral hospital over a 1-year period. The data examined included drug-related variables, use of health-care resources, transportation and work productivity losses. Effectiveness was measured as the proportion of patients achieving a reduction of at least 75% with respect to the baseline value for the Psoriasis Area Severity Index (PASI 75) during the first 52 weeks of treatment. RESULTS: No statistically significant differences in effectiveness between etanercept (n = 135) and adalimumab (n = 48) were found (PASI 75 80% vs. 85.7%; RR = 1.07 [0.90, 1.27]; RRA = 5.7 [-8.9, 20.2]; p = 0.943). There were no significant differences in total cost per patient with etanercept as compared to adalimumab (14,843.73 ± 6,178.98
ABSTRACT
No disponible